Cargando…

Gut Microbiota: Novel Therapeutic Target of Ginsenosides for the Treatment of Obesity and Its Complications

Obesity, generally characterized by excessive lipid accumulation, is a metabolic threat worldwide due to its rapid growth in global prevalence. Ginsenosides are crucial components derived from natural plants that can confer metabolic benefits for obese patients. Considering the low bioavailability a...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhuang, Tongxi, Li, Wei, Yang, Li, Wang, Zhengtao, Ding, Lili, Zhou, Mingmei
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8429618/
https://www.ncbi.nlm.nih.gov/pubmed/34512356
http://dx.doi.org/10.3389/fphar.2021.731288
_version_ 1783750566286983168
author Zhuang, Tongxi
Li, Wei
Yang, Li
Wang, Zhengtao
Ding, Lili
Zhou, Mingmei
author_facet Zhuang, Tongxi
Li, Wei
Yang, Li
Wang, Zhengtao
Ding, Lili
Zhou, Mingmei
author_sort Zhuang, Tongxi
collection PubMed
description Obesity, generally characterized by excessive lipid accumulation, is a metabolic threat worldwide due to its rapid growth in global prevalence. Ginsenosides are crucial components derived from natural plants that can confer metabolic benefits for obese patients. Considering the low bioavailability and degradable properties of ginsenosides in vivo, it should be admitted that the mechanism of ginsenosides on anti-obesity contribution is still obscure. Recently, studies have indicated that ginsenoside intervention has beneficial metabolic effects on obesity and its complications because it allows for the correction of gut microbiota dysbiosis and regulates the secretion of related endogenous metabolites. In this review, we summarize the role of gut microbiota in the pathogenetic process of obesity, and explore the mechanism of ginsenosides for ameliorating obesity, which can modulate the composition of gut microbiota by improving the metabolism of intestinal endogenous substances and alleviating the level of inflammation. Ginsenosides are expected to become a promising anti-obesity medical intervention in the foreseeable clinical settings.
format Online
Article
Text
id pubmed-8429618
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-84296182021-09-11 Gut Microbiota: Novel Therapeutic Target of Ginsenosides for the Treatment of Obesity and Its Complications Zhuang, Tongxi Li, Wei Yang, Li Wang, Zhengtao Ding, Lili Zhou, Mingmei Front Pharmacol Pharmacology Obesity, generally characterized by excessive lipid accumulation, is a metabolic threat worldwide due to its rapid growth in global prevalence. Ginsenosides are crucial components derived from natural plants that can confer metabolic benefits for obese patients. Considering the low bioavailability and degradable properties of ginsenosides in vivo, it should be admitted that the mechanism of ginsenosides on anti-obesity contribution is still obscure. Recently, studies have indicated that ginsenoside intervention has beneficial metabolic effects on obesity and its complications because it allows for the correction of gut microbiota dysbiosis and regulates the secretion of related endogenous metabolites. In this review, we summarize the role of gut microbiota in the pathogenetic process of obesity, and explore the mechanism of ginsenosides for ameliorating obesity, which can modulate the composition of gut microbiota by improving the metabolism of intestinal endogenous substances and alleviating the level of inflammation. Ginsenosides are expected to become a promising anti-obesity medical intervention in the foreseeable clinical settings. Frontiers Media S.A. 2021-08-27 /pmc/articles/PMC8429618/ /pubmed/34512356 http://dx.doi.org/10.3389/fphar.2021.731288 Text en Copyright © 2021 Zhuang, Li, Yang, Wang, Ding and Zhou. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Pharmacology
Zhuang, Tongxi
Li, Wei
Yang, Li
Wang, Zhengtao
Ding, Lili
Zhou, Mingmei
Gut Microbiota: Novel Therapeutic Target of Ginsenosides for the Treatment of Obesity and Its Complications
title Gut Microbiota: Novel Therapeutic Target of Ginsenosides for the Treatment of Obesity and Its Complications
title_full Gut Microbiota: Novel Therapeutic Target of Ginsenosides for the Treatment of Obesity and Its Complications
title_fullStr Gut Microbiota: Novel Therapeutic Target of Ginsenosides for the Treatment of Obesity and Its Complications
title_full_unstemmed Gut Microbiota: Novel Therapeutic Target of Ginsenosides for the Treatment of Obesity and Its Complications
title_short Gut Microbiota: Novel Therapeutic Target of Ginsenosides for the Treatment of Obesity and Its Complications
title_sort gut microbiota: novel therapeutic target of ginsenosides for the treatment of obesity and its complications
topic Pharmacology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8429618/
https://www.ncbi.nlm.nih.gov/pubmed/34512356
http://dx.doi.org/10.3389/fphar.2021.731288
work_keys_str_mv AT zhuangtongxi gutmicrobiotanoveltherapeutictargetofginsenosidesforthetreatmentofobesityanditscomplications
AT liwei gutmicrobiotanoveltherapeutictargetofginsenosidesforthetreatmentofobesityanditscomplications
AT yangli gutmicrobiotanoveltherapeutictargetofginsenosidesforthetreatmentofobesityanditscomplications
AT wangzhengtao gutmicrobiotanoveltherapeutictargetofginsenosidesforthetreatmentofobesityanditscomplications
AT dinglili gutmicrobiotanoveltherapeutictargetofginsenosidesforthetreatmentofobesityanditscomplications
AT zhoumingmei gutmicrobiotanoveltherapeutictargetofginsenosidesforthetreatmentofobesityanditscomplications